Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM

Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM

Item
http://www.wikidata.org/entity/Q28331340
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsFenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndromeEffects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study.Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.Cardiometabolic impact of non-statin lipid lowering therapies.Dyslipidaemia in non-insulin dependent diabetes: the need for a clinical intervention trial.Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice.Combination of peroxisome proliferator-activated receptor α/γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion.Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia.Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice.
P2860

Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM

Item
http://www.wikidata.org/entity/Q28331340
description
1990 nî lūn-bûn
@nan
1990 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@ast
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@en
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@nl
type
label
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@ast
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@en
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@nl
prefLabel
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@ast
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@en
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Lowering of plasma glucose con ...... th moderately controlled NIDDM
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921